Iodixanol vs Iopromide Study Abstract Presented at American College of Cardiology 2008
The prospective, randomized, double-blind, single-center study is authored by Bin Nie, M.D. and colleagues from Beijing Anzhen Hospital, Beijing, People's Republic of China.
The preliminary conclusion of the study indicates that iso-osmolar CM iodixanol appears to be associated with a significantly lower incidence of Contrast Induced Nephropathy (CIN) and composite cardiovascular events compared with the low-osmolar CM iopromide in patients with CKD undergoing coronary angiography with or without PCI. Additional findings included the image quality of the two agents does not differ. The findings support the class 1A recommendation from the 2007 AHA/ACC guidelines for the management of patients with Unstable-Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) and the AHA/ACC/SCAI 2007 Update of the Guidelines for PCI, recommending the use of isosmolar contrast in patients with CKD who undergo coronary arteriography.
ABOUT VISIPAQUE, SELECT SAFETY INFORMATION:
In the U.S., Visipaque(TM) (iodixanol) Injection Nonionic Isosmolar VISIPAQUE IS NOT FOR INTRATHECAL USE. All nonionic, iodinated contrast media currently available inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.
Before administering this product please see the product's full prescribing information located at www.gehealthcare.com. Because indications vary, consult your country-specific prescribing information.
ABOUT GE HEALTHCARE:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE:GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
Contact
GE Healthcare
Ryan Fitzgerald
414-530-2735
ryan.fitzgerald@ge.com
